Experimental leishmaniasis drug tested in healthy volunteers
NCT ID NCT04504435
First seen May 10, 2026 · Last updated May 10, 2026
Summary
This was the first study to give GSK3494245 to humans, testing its safety and how the body handles it. 59 healthy adults received up to three single doses of the drug or a placebo. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Cambridge, CB2 2GG, United Kingdom
Conditions
Explore the condition pages connected to this study.